TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has completed a Phase 3 program for ublituximab, an investigational glycoengineered monoclonal antibody that targets a unique epitope on CD20-expressing B-cells, to treat patients with relapsing forms of multiple sclerosis (RMS).
Company Details
- Employees
- 439
- Founded
- -
- Address
- New York, Ny 10014, Us
- Phone
- (212)554-4484
- ir****@****inc.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- tgtherapeutics.com
- Keywords
- Biotechnology, hematological malignancies, non-Hodgkin's lymphoma, multiple sclerosis, b-cell diseases, ublituximab, umbralisib.
- HQ
- New York, NY
Tg Therapeutics, Inc. Questions
Tg Therapeutics, Inc.'s helpline number is (212)554-4484
Tg Therapeutics, Inc.'s website is tgtherapeutics.com
Tg Therapeutics, Inc.'s LinkedIn profile is https://www.linkedin.com/company/tg-therapeutics
Tg Therapeutics, Inc. has
439 employees.
View email and phone details for 439
employees at Tg Therapeutics, Inc..
Tg Therapeutics, Inc.'s industry is
Biotechnology Research
Tg Therapeutics, Inc.'s top competitors are
Rocket Pharmaceuticals,
Vertex Pharmaceuticals,
Alnylam Pharmaceuticals,
Jazz Pharmaceuticals,
Novartis,
Apellis Pharmaceuticals,
Ovid Therapeutics,
Karyopharm Therapeutics Inc.,
Adc Therapeutics,
Biogen.
Tg Therapeutics, Inc.'s support email address is ir@tgtxinc.com
Tg Therapeutics, Inc.'s categories are Biotechnology Research
Tg Therapeutics, Inc.'s founding year is 2011
